The best example of the key role of non-coding RNAs in the development of new drugs for cancer treatment is the use of venetoclax in patients with high BCL-2 protein levels, correlated with deletions on chromosome 13 and loss of miR-15a and miR-16-1. This evidence concerns the gene BCL2 and cancer.